188 related articles for article (PubMed ID: 20197691)
1. Early detection of Alzheimer's disease with PET imaging.
Berti V; Osorio RS; Mosconi L; Li Y; De Santi S; de Leon MJ
Neurodegener Dis; 2010; 7(1-3):131-5. PubMed ID: 20197691
[TBL] [Abstract][Full Text] [Related]
2. Pre-clinical detection of Alzheimer's disease using FDG-PET, with or without amyloid imaging.
Mosconi L; Berti V; Glodzik L; Pupi A; De Santi S; de Leon MJ
J Alzheimers Dis; 2010; 20(3):843-54. PubMed ID: 20182025
[TBL] [Abstract][Full Text] [Related]
3. Optimizing Use of Neuroimaging Tools in Evaluation of Prodromal Alzheimer's Disease and Related Disorders.
Raji CA; Torosyan N; Silverman DHS
J Alzheimers Dis; 2020; 77(3):935-947. PubMed ID: 32804147
[TBL] [Abstract][Full Text] [Related]
4. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
5. Positron emission tomography radiopharmaceuticals for imaging brain Beta-amyloid.
Vallabhajosula S
Semin Nucl Med; 2011 Jul; 41(4):283-99. PubMed ID: 21624562
[TBL] [Abstract][Full Text] [Related]
6. Validation of a New Imaging Technique Using the Glucose Metabolism to Amyloid Deposition Ratio in the Diagnosis of Alzheimer's Disease.
Takahashi R; Ishii K; Yokoyama K; For The Alzheimer S Disease Neuroimaging Initiative EY
Curr Alzheimer Res; 2017; 14(2):161-168. PubMed ID: 27334941
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer's Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis.
Khosravi M; Peter J; Wintering NA; Serruya M; Shamchi SP; Werner TJ; Alavi A; Newberg AB
J Alzheimers Dis; 2019; 70(4):1197-1207. PubMed ID: 31322568
[TBL] [Abstract][Full Text] [Related]
8. Amyloid PET, FDG-PET or MRI? - the power of different imaging biomarkers to detect progression of early Alzheimer's disease.
Ortner M; Drost R; Hedderich D; Goldhardt O; Müller-Sarnowski F; Diehl-Schmid J; Förstl H; Yakushev I; Grimmer T
BMC Neurol; 2019 Oct; 19(1):264. PubMed ID: 31672138
[TBL] [Abstract][Full Text] [Related]
9. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.
Foster NL; Wang AY; Tasdizen T; Fletcher PT; Hoffman JM; Koeppe RA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S29-36. PubMed ID: 18631997
[TBL] [Abstract][Full Text] [Related]
10. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD.
Mosconi L
Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):486-510. PubMed ID: 15747152
[TBL] [Abstract][Full Text] [Related]
11. Visual Versus Fully Automated Analyses of 18F-FDG and Amyloid PET for Prediction of Dementia Due to Alzheimer Disease in Mild Cognitive Impairment.
Grimmer T; Wutz C; Alexopoulos P; Drzezga A; Förster S; Förstl H; Goldhardt O; Ortner M; Sorg C; Kurz A
J Nucl Med; 2016 Feb; 57(2):204-7. PubMed ID: 26585056
[TBL] [Abstract][Full Text] [Related]
12. PET Imaging for Early Detection of Alzheimer's Disease: From Pathologic to Physiologic Biomarkers.
Bao W; Jia H; Finnema S; Cai Z; Carson RE; Huang YH
PET Clin; 2017 Jul; 12(3):329-350. PubMed ID: 28576171
[TBL] [Abstract][Full Text] [Related]
13. Early differential diagnosis between Alzheimer's disease and dementia with Lewy bodies: Comparison between (18)F-FDG PET and (123)I-IMP SPECT.
Chiba Y; Iseki E; Fujishiro H; Ota K; Kasanuki K; Suzuki M; Hirayasu Y; Arai H; Sato K
Psychiatry Res Neuroimaging; 2016 Mar; 249():105-12. PubMed ID: 26857415
[TBL] [Abstract][Full Text] [Related]
14. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum.
Tosun D; Schuff N; Jagust W; Weiner MW;
Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336
[TBL] [Abstract][Full Text] [Related]
15. Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments.
Reiman EM;
Neurobiol Aging; 2011 Dec; 32 Suppl 1(Suppl 1):S44-7. PubMed ID: 21983241
[TBL] [Abstract][Full Text] [Related]
16. Concordance between brain
Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
[TBL] [Abstract][Full Text] [Related]
17. FDG-PET and amyloid-PET imaging: the diverging paths.
Perani D
Curr Opin Neurol; 2014 Aug; 27(4):405-13. PubMed ID: 24927239
[TBL] [Abstract][Full Text] [Related]
18. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
[TBL] [Abstract][Full Text] [Related]
19. Multiscale deep neural network based analysis of FDG-PET images for the early diagnosis of Alzheimer's disease.
Lu D; Popuri K; Ding GW; Balachandar R; Beg MF;
Med Image Anal; 2018 May; 46():26-34. PubMed ID: 29502031
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Positron Emission Tomography in Preventive Alzheimer's Disease Drug Trials, Critical Barriers from Imaging Science Perspective.
Shokouhi S; Campbell D; Brill AB; Gwirtsman HE;
Brain Pathol; 2016 Sep; 26(5):664-71. PubMed ID: 27327527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
